Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8956252 | Hematology/Oncology and Stem Cell Therapy | 2018 | 9 Pages |
Abstract
Dose difference of rATG-F did not influence survival parameters; however, increasing the dose to 30â¯mg/kg seems to be effective for reducing cGVHD with an increase in infection rate requiring close monitoring of infections in AML patients who received myeloablative fludarabine/busulfan conditioning.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Can Boga, Mahmut Yeral, CiÄdem Gereklioglu, Suheyl Asma, Erkan Maytalman, Pelin Aytan, Ilknur Kozanoglu, Cagla Sariturk, Hakan Ozdogu,